BMS Reyataz complaint presages easier exclusivity enforcement in 'tricky' markets?
This article was originally published in Scrip
Voluntary license agreements could become an increasingly popular means for originator companies to protect brand exclusivity in global markets where there is money to be made but little protection for intellectual property rights. A breach of contract complaint brought by Bristol-Myers Squibb in the US against Mylan/Matrix will put the theory to the test.
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.